US biotech BioSig Technologies’ subsidiary ViralClear has been cleared by the FDA to start a phase 2 trial of its antiviral drug merimepodib in patients who are severely ill with COVID-19.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,